Current status and perspective on regenerative medicine for spinal cord injury using iPS cell

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Stimulated by the 2012 Nobel Prize in Physiology or Medicine awarded for Shinya Yamanaka and Sir John Gurdon, there is an increasing interest in the iPS cells and reprogramming technologies in medical science. While iPS cells are expected to open new era providing enormous opportunities in the biomedical sciences in terms of cell therapies for regenerative medicine, safety-related concerns for iPS cell-based cell therapy should be resolved prior to the clinical application of iPS cells. In this symposium, the pre-clinical investigations of cell therapy for SCI using neural stem/progenitor cells derived from iPS cells, and their safety issues in vivo are outlined.

Original languageEnglish
Pages (from-to)1013-1016
Number of pages4
JournalClinical Neurology
Volume53
Issue number11
DOIs
Publication statusPublished - 2013

Fingerprint

Regenerative Medicine
Spinal Cord Injuries
Cell- and Tissue-Based Therapy
Nobel Prize
Safety
Neural Stem Cells
Stem Cells
Medicine
Technology

Keywords

  • Cell transplantation
  • Neural progenitor cells
  • Spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Cite this

Current status and perspective on regenerative medicine for spinal cord injury using iPS cell. / Nakamura, Masaya; Toyama, Yoshiaki; Okano, Hideyuki.

In: Clinical Neurology, Vol. 53, No. 11, 2013, p. 1013-1016.

Research output: Contribution to journalArticle

@article{7b30ab7c981246989fe58ecc4f414210,
title = "Current status and perspective on regenerative medicine for spinal cord injury using iPS cell",
abstract = "Stimulated by the 2012 Nobel Prize in Physiology or Medicine awarded for Shinya Yamanaka and Sir John Gurdon, there is an increasing interest in the iPS cells and reprogramming technologies in medical science. While iPS cells are expected to open new era providing enormous opportunities in the biomedical sciences in terms of cell therapies for regenerative medicine, safety-related concerns for iPS cell-based cell therapy should be resolved prior to the clinical application of iPS cells. In this symposium, the pre-clinical investigations of cell therapy for SCI using neural stem/progenitor cells derived from iPS cells, and their safety issues in vivo are outlined.",
keywords = "Cell transplantation, Neural progenitor cells, Spinal cord injury",
author = "Masaya Nakamura and Yoshiaki Toyama and Hideyuki Okano",
year = "2013",
doi = "10.5692/clinicalneurol.53.1013",
language = "English",
volume = "53",
pages = "1013--1016",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Current status and perspective on regenerative medicine for spinal cord injury using iPS cell

AU - Nakamura, Masaya

AU - Toyama, Yoshiaki

AU - Okano, Hideyuki

PY - 2013

Y1 - 2013

N2 - Stimulated by the 2012 Nobel Prize in Physiology or Medicine awarded for Shinya Yamanaka and Sir John Gurdon, there is an increasing interest in the iPS cells and reprogramming technologies in medical science. While iPS cells are expected to open new era providing enormous opportunities in the biomedical sciences in terms of cell therapies for regenerative medicine, safety-related concerns for iPS cell-based cell therapy should be resolved prior to the clinical application of iPS cells. In this symposium, the pre-clinical investigations of cell therapy for SCI using neural stem/progenitor cells derived from iPS cells, and their safety issues in vivo are outlined.

AB - Stimulated by the 2012 Nobel Prize in Physiology or Medicine awarded for Shinya Yamanaka and Sir John Gurdon, there is an increasing interest in the iPS cells and reprogramming technologies in medical science. While iPS cells are expected to open new era providing enormous opportunities in the biomedical sciences in terms of cell therapies for regenerative medicine, safety-related concerns for iPS cell-based cell therapy should be resolved prior to the clinical application of iPS cells. In this symposium, the pre-clinical investigations of cell therapy for SCI using neural stem/progenitor cells derived from iPS cells, and their safety issues in vivo are outlined.

KW - Cell transplantation

KW - Neural progenitor cells

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84891758977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891758977&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.53.1013

DO - 10.5692/clinicalneurol.53.1013

M3 - Article

VL - 53

SP - 1013

EP - 1016

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -